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COPD (chronic obstructive pulmonary disease) is a common lung disease characterized by airflow limitation and systemic
inflammation. Recently, adipose tissuemediated inflammation has gathered increasing interest in the pathogenesis of the disease. In
this study, we investigated the role of novel adipocytokines nesfatin-1 and visfatin in COPD bymeasuring if they are associated with
the inflammatory activity, lung function, or symptoms. Plasma levels ofNUCB2/nesfatin-1 and visfatinweremeasured togetherwith
IL-6, IL-8, TNF-𝛼, andMMP-9, lung function, exhaled nitric oxide, and symptoms in 43male patients with emphysematous COPD.
The measurements were repeated in a subgroup of the patients after four weeks’ treatment with inhaled fluticasone. Both visfatin
and NUCB2/nesfatin-1 correlated positively with plasma levels of IL-6 (𝑟 = 0.341, 𝑃 = 0.027 and rho = 0.401, 𝑃 = 0.008, resp.) and
TNF-𝛼 (𝑟 = 0.305, 𝑃 = 0.052 and rho = 0.329, 𝑃 = 0.033, resp.) and NUCB2/nesfatin-1 also with IL-8 (rho = 0.321, 𝑃 = 0.036)
in patients with COPD. Further, the plasma levels of visfatin correlated negatively with pulmonary diffusing capacity (𝑟 = −0.369,
𝑃 = 0.016). Neither of the adipokines was affected by fluticasone treatment and they were not related to steroid-responsiveness.The
present results introduce adipocytokines NUCB2/nesfatin-1 and visfatin as novel factors associated with systemic inflammation in
COPD and suggest that visfatin may mediate impaired pulmonary diffusing capacity.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a disorder
characterized by persistent airflow limitation with systemic
manifestations [1]. In addition to the inflammatory process
in the lungs, there is a low-grade systemic inflammation
which is linked to the pathogenesis of the comorbidities
present in COPD [2–4]. It is not known whether systemic
inflammation is a spillover of the inflammation present in
the lungs or if pulmonary manifestations are one form of
expression of this systemic disease [3, 5]. Smoking, lung
hyperinflation, tissue hypoxia, and skeletal muscle dysfunc-
tion have been suggested as possible factors involved in
the pathogenesis of the systemic inflammation in COPD
[2]. Recently, adipose tissue mediated inflammation has
gathered increasing interest as a significant mechanism in
inducing and promoting systemic inflammation in COPD
[4].
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Adipokines (also known as adipocytokines) are protein
mediators secreted by adipose tissue and they are involved
not only in the regulation of energy metabolism but also in
inflammatory responses in many chronic inflammatory dis-
eases [6, 7]. There is increasing body of evidence supporting
a significant role of adipokines adiponectin and leptin in the
inflammatory processes in COPD [8], but only a little or
nothing is known about the other adipokines like nesfatin-
1 and visfatin in inflammatory lung diseases. So far, there are
no previous publications on nesfatin-1 and only a few reports
on visfatin in COPD.
Nesfatin-1 is a novel adipokine discovered in 2006 and at
first linked to appetite and body weight control in rats [9].
Nesfatin-1 is expressed in human adipose tissue and TNF-
𝛼, IL-6, insulin, and dexamethasone have been shown to
increase its secretion [10]. Nesfatin-1 has also been shown to
regulate inflammatory responses and cell apoptosis in rats [11]
and to have cardioprotective effects in human studies [12].
There are only two previous publications on nesfatin-1 in lung
diseases: one concerning changes in fat mass in lung cancer
[13] and the other on cystic fibrosis [14].
Visfatin, also known as nicotinamide phosphoribosyl-
transferase (NAMPT) and previously identified as pre-B cell
colony-enhancing factor (PBEF), was originally discovered
in lymphocytes, bone marrow, liver, and muscle [15]. Later,
visfatinwas identified also in the lungs [16], and, interestingly,
the proinflammatory cytokine IL-1 has been reported to
enhance visfatin expression in pulmonary epithelial and
endothelial cells in vitro [17]. Also proinflammatory cytokines
IL-6 [18] and TNF-𝛼 [19] have been shown to induce
the expression of visfatin. Granulocytes and monocytes are
major sources of visfatin [20], and it is also produced by
macrophages and adipocytes [21]. Visfatin is a proinflamma-
tory cytokine involved in the regulation of inflammation and
innate immunity [22, 23]. In the lungs, visfatin is associated
with acute lung injury (ALI) [24] and the inhibition of
visfatin synthesis has been shown to attenuate inflammation
and apoptosis associated with severe virus infection in lung
endothelium [25].
In the present study, we measured the plasma levels of
visfatin and NUCB2/nesfatin-1 in patients with COPD and
in controls and investigated if these adipokines are associated
with other markers of inflammation, lung function, the
degree of emphysema, and symptoms or with the response
to inhaled glucocorticoids in patients with COPD.
2. Materials and Methods
2.1. Subjects and Study Design. Forty-three steroid-naı¨ve
male patients with COPD were recruited among subjects
referred from primary care for diagnostic assessment to the
Department of Respiratory Medicine at Tampere University
Hospital, Tampere, Finland. COPD diagnosis was based on
GOLD strategy paper [1] and the inclusion criteria were
smoking history of at least 20 pack-years, symptoms of
COPD (cough, sputum production, and dyspnoea), post-
bronchodilator FEV
1
/FVC < 0.7, reversibility of FVC or FEV
1
induced by ß
2
-agonist < 12% or 200mL, and pulmonary
emphysema visible on high resolution computed tomography
(HRCT) of the lungs. Patients with a diagnosis or clinical
history of asthma or diabetes were excluded. Ten (23%) of
the patients had hypertension and five (12%) had hyper-
cholesterolemia while the number of patients with other
diseases was too small for any statistical analysis. Forty-one
age-matched nonsmoking healthy males with normal lung
function served as controls.
Spirometry, fractional exhaled nitric oxide concentra-
tion (FENO), and pulmonary diffusing capacity per unit of
alveolar volume standardized for haemoglobin concentration
(Hb-𝐷L,CO/𝑉𝐴) were measured, high resolution computed
tomography (HRCT) of the lungs was performed, and symp-
tomswere scoredwith St. George’s RespiratoryQuestionnaire
(SGRQ) in patients with COPD. A venous blood sample was
drawn in both groups. The same measurements excluding
HRCT were repeated in twenty-seven patients with COPD
after 4weeks of treatmentwith inhaled fluticasone propionate
(Flixotide Diskus 500 𝜇g b.i.d.; GlaxoSmithKline, Ware, UK).
2.2. Adipokines and Inflammatory Markers. Plasma concen-
trations of NUCB2/nesfatin-1, visfatin, interleukin 6 (IL-6),
interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-𝛼),
and matrix metalloproteinase 9 (MMP-9) were determined
by enzyme immunoassay by using the following reagents:
NUCB2/nesfatin, TNF-𝛼, andMMP-9: R&D Systems Europe
Ltd., Abingdon, UK; visfatin: Phoenix Pharmaceuticals Inc.,
Karlsruhe, Germany; IL-6: Sanquin, Amsterdam, Nether-
lands; and IL-8: BD Biosciences, San Diego, CA, USA.
According to the manufacturer, the nesfatin-1 antibody
detects the protein nucleobinding-2 (NUCB2) in addition to
nesfatin-1 which is derived fromNUCB2 by posttranslational
processing. Therefore, the term NUCB2/nesfatin-1 is used
when referring to our own measurements. The detection
limits and interassay coefficients of variation were 7.8 pg/mL
and 11.6% for NUCB2/nesfatin-1, 0.1 ng/mL and 8.3% for
visfatin, 0.3 pg/mL and 7.6% for IL-6, 1.56 pg/mL and 7.0% for
IL-8, 0.5 pg/mL and 6.5% for TNF-𝛼, and 7.8 pg/mL and 6.0%
for MMP-9.
2.3. Lung Function, Exhaled NO, HRCT, and Symptom Scor-
ing. Spirometry was measured (Vmax 20C, Sensor-Medics,
Yorba Linda, CA, USA) before and after 400 𝜇g of inhaled
salbutamol. Pulmonary diffusing capacity wasmeasuredwith
Vmax 20C, Sensor-Medics.
Fractional exhaled nitric oxide concentration at exhala-
tion flow rate of 50mL/s (FENO
0.05
) was measured with a
SieversNOA280NO-analyzer (Sievers Instruments, Boulder,
CO, USA) as previously described [26].
Airway wall thickness and the extent of emphysema on
pulmonary high resolution computed tomography (HRCT)
(Siemens Somatom Plus 4, Siemens Medical, Erlangen, Ger-
many)were assessed by two experienced thoracic radiologists
(Ritva Ja¨rvenpa¨a¨ and LeaKo¨o¨bi) as previously described [27].
The subjects filled in the Finnish translation of St.
George’s Respiratory Questionnaire (SGRQ) containing
questions and scoring on three aspects of the disease
(symptom frequency and severity, activities that cause or are
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Table 1: Plasma levels of adipokines and other inflammatory markers in patients with COPD and healthy controls.
COPD Controls 𝑃 value
𝑁 43 41
NUCB2/nesfatin-1 (pg/mL) 75.0 [26.2–103.1] 43.1 [17.9–86.6] 0.117
Visfatin (ng/mL) 7.5 ± 1.5 8.9 ± 2.3 0.002
IL-6 (pg/mL) 1.5 ± 1.3 1.5 ± 1.2 0.888
MMP-9 (ng/mL) 40.6 ± 17.3 33.9 ± 12.6 0.048
Values are presented as mean ± SD for normally distributed data and as median [interquartile range] for nonnormally distributed data.
IL-6: interleukin 6; MMP-9: matrix metalloproteinase 9.
Table 2: Correlations between adipokines and other parameters in patients with COPD (𝑛 = 43).
NUCB2/nesfatin-1 Visfatin
FEV1 (% pred)
rho = 0.097 𝑟 = 0.127
𝑃 = 0.535 𝑃 = 0.422
FENO0.05 (ppb)
rho = −0.035 𝑟 = 0.040
𝑃 = 0.823 𝑃 = 0.802
Hb-𝐷L,CO/𝑉𝐴 (% pred)
rho = −0.103 𝑟 = −0.369
𝑃 = 0.512 𝑃 = 0.016
Emphysema percentage (%) rho = 0.076 𝑟 = 0.204
𝑃 = 0.626 𝑃 = 0.194
IL-6 (pg/mL) rho = 0.401 𝑟 = 0.341
𝑃 = 0.008 𝑃 = 0.027
IL-8 (pg/mL) rho = 0.321 𝑟 = 0.121
𝑃 = 0.036 𝑃 = 0.443
TNF-𝛼 (pg/mL) rho = 0.329 𝑟 = 0.305
𝑃 = 0.033 𝑃 = 0.052
Thedistribution of nesfatin-1 was skewedwhile visfatin was normally distributed; therefore Spearman’s rho and Pearson’s 𝑟were used to analyze the correlations
of NUCB2/nesfatin-1 and visfatin, respectively, to the other parameters presented.
FEV1: forced expiratory volume in 1 second; FENO0.05: fractional exhaled nitric oxide concentration at exhalation flow rate of 50mL/s; Hb-𝐷L,CO/𝑉𝐴: diffusing
capacity for carbon monoxide per unit of alveolar volume standardized for haemoglobin; IL: interleukin; TNF: tumor necrosis factor.
limited by breathlessness, and the impact of the disease
on social functioning including psychological disturbances
resulting from the disease) to obtain a total score. The scale
has a range from 0 to 100, with higher scores representing
more severe disease.
2.4. Statistics. Visfatin was normally distributed, while the
distribution of NUCB2/nesfatin-1 was skewed and could
not be normalised after log-transformation. 𝑡-test or Mann-
Whitney test was used to examine differences between
healthy controls and patients with COPD, where appropriate.
Pearson’s 𝑟 or Spearman’s rho was used to analyse the
correlations between adipokines and other inflammatory
markers or markers of disease severity, where appropriate.
Changes in plasma levels of adipokines and other measures
during fluticasone treatment were analysed with paired 𝑡-
test or Wilcoxon’s test, where appropriate. The results are
presented as mean ± SD for normally distributed data and
as median (interquartile range) for nonnormally distributed
data. SPSS 19 software (SPSS Inc., Chicago, Illinois, USA) was
used in the statistical analysis.
2.5. Ethics. The study was approved by the Ethics Committee
of Tampere University Hospital, Tampere, Finland, and com-
plies with the declaration of Helsinki. All subjects provided
their written informed consent.
3. Results
3.1. Characteristics of the Subjects. In the patientswithCOPD,
the mean age was 59.5 ± 7.8 (mean ± SD) years and the mean
forced expiratory volume in 1 second (FEV
1
) was 53 ± 14%
of the predicted. The age- and sex-matched healthy controls
had normal lung function and there were no significant
differences in BMI between the patients with COPD and
the controls (25.8 ± 4.2 versus 26.7 ± 3.9 kg/m2, resp., 𝑃 =
0.332). Plasma levels of adipokines NUCB2/nesfatin-1 and
visfatin in the patients with COPD and controls are given
in Table 1. Visfatin levels were lower in COPD, but plasma
NUCB2/nesfatin-1 levels did not differ from controls. Neither
of the adipokines measured differed between ex-smokers
(𝑛 = 10) and current smokers (𝑛 = 33) or between the
patients with or without hypertension (𝑛 = 10) or between
the patients with or without hypercholesterolemia (𝑛 = 5) in
the COPD group.
3.2. Correlations between Adipokines and Other Parame-
ters. Correlations between adipokines and other parame-
ters in patients with COPD are given in Table 2. Both
NUCB2/nes fatin-1 and visfatin correlated with IL-6 in the
patients with COPD but not in controls. Therefore, two
other proinflammatory cytokines, that is, TNF-𝛼 and IL-8,
were also measured in patients with COPD. Interestingly,
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NUCB2/nesfatin-1 and visfatin correlated positively with
TNF-𝛼 and NUCB2/nesfatin-1 also with IL-8. A negative
correlation was seen between visfatin and pulmonary dif-
fusing capacity (Hb-𝐷L,CO/𝑉𝐴) suggesting that visfatin is
associatedwith parenchymal impairment.The adipokines did
not correlate with BMI, radiological changes, levels of MMP-
9, exhaled nitric oxide, or symptoms score.
3.3. The Treatment Responses. Four weeks of treatment with
inhaled fluticasone caused no significant changes in plasma
levels of NUCB2/nesfatin-1 (before: 75.0 (18.3–119.4) pg/mL,
after: 61.1 (17.5–116.1) pg/mL, 𝑃 = 0.399) or visfatin (before:
7.9 ± 1.5 ng/mL, after: 8.0 ± 1.4 ng/mL, 𝑃 = 0.804). As
expected, the treatment decreased St. George’s Respiratory
Questionnaire total score describing the impact of the disease
(before: 36.4±15.6, after: 30.8±16.0,𝑃 = 0.015) and symptom
score (before: 55.2 ± 22.1, after: 38.0 ± 23.2, 𝑃 < 0.001). The
baseline plasma levels of NUCB2/nesfatin-1 or visfatin did
not correlate with the degree of fluticasone induced changes
in either symptoms or lung function in COPD (data not
shown).
4. Discussion
Themain findings in the present studywere thatNUCB2/nes-
fatin-1 and visfatin correlated positivelywith systemic inflam-
mation and, further, visfatin was associated with parenchy-
mal impairment in patients with emphysematous COPD.
This suggests that NUCB2/nesfatin-1 and visfatin may have
a role in the inflammatory processes in COPD.
Originally, adipose-tissue-derived adipokines were found
to regulate energy metabolism and to be associated with the
chronic low-grade inflammation present in obesity-related
metabolic disturbances and inflammatory diseases [28, 29].
Later adipokines have also been linked to inflammatory
lung diseases like asthma and COPD [8] and the majority
of the studies have concentrated on the role of leptin and
adiponectin in these diseases. It has been suggested that high
circulating leptin and low adiponectin predict asthma inde-
pendent of obesity and that low leptin and high adiponectin
are associated with stable COPD [30]. The results on the
association between adipokines and COPD are, however, still
conflicting and the studies are not covering all adipokines
such as visfatin, which is known to be associated with other
chronic inflammatory and destructive syndromes such as
rheumatic diseases [31].
We found that NUCB2/nesfatin-1 and visfatin concentra-
tions in plasma correlated with circulating levels of IL-6 and
TNF-𝛼 and NUCB2/nesfatin-1 also with IL-8 suggesting that
these adipokines may have a role in the systemic inflamma-
tion in COPD. Neutrophils and macrophages are significant
cell types in the pathophysiology of COPD [32].Macrophages
are also major sources of IL-6 and TNF-𝛼 [32] and neu-
trophils of IL-8 [33]. As activated macrophages also secrete
adipokines [6], the association between adipocytokines
nesfatin-1 and visfatin and proinflammatory cytokines IL-
6 and TNF-𝛼 in COPD may be linked to the activation
of macrophages. Further, IL-6 has been shown to induce
the expression of both visfatin [18] and nesfatin-1 [10], and
additionally it has been reported that TNF-𝛼 is able to
provoke both nesfatin-1 [10] and visfatin secretions [19].
Moreover, it has been presented that visfatin itself can
induce the production of TNF-𝛼 and especially IL-6 [22].
Also, previous reports have shown that visfatin correlates
positively with IL-6 [34] and with CRP and TNF-𝛼 without
association with BMI in patients with COPD [35], but the
current study is the first report on NUCB2/nesfatin-1 in
COPD.
Interestingly, we also found a negative correlation
between visfatin and pulmonary diffusing capacity suggest-
ing that visfatin is associated with parenchymal impairment
in emphysematous COPD. In COPD, diffusing capacity may
be decreased due to loss of alveolar surface and due to
impaired diffusivity because of inflammation and oedema
in the alveolar walls. As visfatin levels were not associ-
ated with the degree of emphysema visible on HRCT, we
suggest that visfatin is related to the inflammatory activity
impairing pulmonary diffusing capacity.This is supported by
the previous findings that inflamed endothelium as well as
lung epithelial cells can produce visfatin [17, 36] which may
promote and amplify lung inflammation and parenchymal
vascular damage present in emphysema [37].
Compared to controls, both higher [35] and lower [38]
plasma visfatin levels have been reported in COPD. In the
current study, plasma visfatin levels were lower in the slightly
overweight men with COPD compared to healthy controls
with similar BMI. Consistent with our result, significantly
lower visfatin levels in normal weight or slightly overweight
men with COPD [38] have been reported, while underweight
men with COPD had increased visfatin levels [35]. Visfatin
is expressed in visceral adipose tissue and higher [20],
lower [39], and unchanged [40] circulating visfatin levels
have been reported in obese compared to normal weight
persons. Accordingly, we and others [35] have not found
any correlation between visfatin and BMI in patients with
COPD. The higher visfatin in underweight COPD patients
reported by Liu and coworkers [35] might be explained by
the fact that COPD patients with lower BMI have usually
more severe systemic inflammation [41] and that visfatin itself
can inhibit neutrophil apoptosis [42] and thus enhance lung
inflammation in COPD patients. Liu et al. also hypothesized
that hypoxemia present in severe COPD may contribute to
increased visfatin [35].
Neither visfatin nor NUCB2/nesfatin-1 concentrations
were changed during inhaled fluticasone treatment in the
current study. This may be explained by the fact that a
short term treatment with inhaled fluticasone likely has no
significant systemic anti-inflammatory effect, and this is also
supported by the present finding that neither IL-6 norMMP-
9 levels changed during the treatment. As far as we know,
there are no other studies on the effect of inhaled gluco-
corticoids on the levels of NUCB2/nesfatin-1 and visfatin,
but in previous studies systemic glucocorticoid treatment
did not alter circulating visfatin levels in humans [43, 44].
Further, in the current study neither of these adipokines
was associated with the treatment responses assessed by lung
function or symptoms. However, in a previous study we
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found that high levels of adiponectin were associated with
steroid-responsiveness in COPD [27].
5. Conclusions
The present results introduce adipocytokines NUCB2/nes-
fatin-1 and visfatin as novel inflammatory factors in sta-
ble emphysematous COPD. Furthermore, visfatin was also
associated with reduced pulmonary diffusing capacity. The
findings suggest that NUCB2/nesfatin-1 and visfatin have a
proinflammatory role in the pathogenesis of emphysema-
tous COPD, but further studies are needed to evaluate if
adipokines could be used as biomarkers for phenotyping or
subgrouping patients with COPD or as anti-inflammatory
drug targets.
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